October 10, 2016

September 29, 2016

The SEC charged Robert Gadimian, former Senior Director of Regulatory Affairs for Puma Biotechnology, with insider trading ahead of the company’s news announcement about its drug to treat breast cancer.  The SEC alleges that Gadimian pocketed more than $1.1 million in illicit profits by secretly purchasing Puma stock and short-term call options based on nonpublic information he learned about positive developments in two clinical trials for Puma’s drug, neratinib.  SEC

*     *     *

If you would like more information or would like to speak to a member of Constantine Cannon’s whistleblower lawyer team, please click here.